There are 2789 resources available
604P - Predictive genomic biomarkers in non-metastatic castration resistant prostate cancer (nmCRPC) treated with androgen receptor pathway inhibitors (ARPi)
Presenter: Richard Gagnon
Session: ePoster Display
605P - Analysis of serial PET imaging and paired Tc99 scans in metastatic castration resistant prostate cancer (mCRPC) treated with enzalutamide
Presenter: Ravi Madan
Session: ePoster Display
606P - Role of serum biomarkers of bone metabolism in metastatic castration-resistance prostate cancer (mCRPC) patients (pts) treated with radium-223 (Ra223): PRORADIUM study final results
Presenter: Nuria Romero Laorden
Session: ePoster Display
607P - Impact of docetaxel on quality of life (QoL) in elderly and non-elderly metastatic castration-resistant prostate cancer (mCRPC) patients (Pts)
Presenter: Silvia Rubio-Novella
Session: ePoster Display
608P - Apalutamide (APA) efficacy and safety in Asian patients with metastatic castration-sensitive prostate cancer (mCSPC)
Presenter: Byung Ha Chung
Session: ePoster Display
609P - Treatment patterns and overall survival (OS) in metastatic castration-sensitive prostate cancer (mCSPC) from 2006 to 2019
Presenter: Stephen Freedland
Session: ePoster Display
611P - Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study
Presenter: Emmanuel Antonarakis
Session: ePoster Display
613P - Chromosomal instability (CIN) biomarker in circulating tumor cells (CTC) may predict for therapy resistance in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niamh Keegan
Session: ePoster Display